{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:46:07Z","timestamp":1788885967336,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jtct.2022.06.013","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T02:22:19Z","timestamp":1655864539000},"page":"572-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-2526","authenticated-orcid":false,"given":"Mohammad O","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.06.013_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"10068","key":"10.1016\/j.jtct.2022.06.013_bib0002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.06.013_bib0003","unstructured":"Kumar SK, Anderson LD, Baljevic M, et al. NCCN Guidelines Version 4.2022. 2021. Available from: www.nccn.org\/patents. Accessed March 2nd, 2022."},{"key":"10.1016\/j.jtct.2022.06.013_bib0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.013_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2022.06.013_bib0006","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: efficacy in high-risk patients","volume":"39","author":"Gay","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0007","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/cncr.34211","article-title":"Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: a meta-analysis of randomized controlled trials","volume":"128","author":"Chakraborty","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.013_bib0008","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.013_bib0009","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/EDBK_320105","article-title":"How to treat high-risk myeloma at diagnosis and relapse","volume":"41","author":"Caro","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.jtct.2022.06.013_bib0010","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0011","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0012","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2014.186","article-title":"Not too little, not too much-just right (Better ways to give high dose melphalan)","volume":"49","author":"Shaw","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0013","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.1994.12.4.759","article-title":"High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma","volume":"12","author":"Cunningham","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0014","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.013_bib0015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bmt.1704424","article-title":"Activity of single-agent melphalan 220-300 mg\/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma","volume":"33","author":"Phillips","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0016","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41409-018-0261-y","article-title":"Final outcomes of escalated melphalan 280 mg\/m 2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival","volume":"54","author":"Hari","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2022.06.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.6545","article-title":"High-dose melphalan on day 2 versus 1 before autologous stem cell transplantation for multiple myeloma","volume":"29","author":"Rakszawski","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0018","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/bmt.2014.56","article-title":"Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma","volume":"49","author":"Parmar","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0019","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/bjh.17980","article-title":"High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma","volume":"196","author":"Aydin","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0020","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","article-title":"Melphalan 200 mg\/m2 versus melphalan 100 mg\/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study","volume":"115","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.013_bib0021","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41409-018-0379-y","article-title":"Melphalan dose in myeloma patients \u226565 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study","volume":"54","author":"Ghilardi","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0022","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.013_bib0023","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/cncr.33831","article-title":"Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older","volume":"127","author":"Munshi","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.06.013_bib0024","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0025","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/bmt.2016.136","article-title":"Melphalan 200 mg\/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival","volume":"51","author":"Sweiss","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0026","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/bmt.2017.198","article-title":"Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis","volume":"52","author":"Mahindra","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0027","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clml.2015.03.003","article-title":"Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients","volume":"15","author":"El Fakih","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.06.013_bib0028","series-title":"Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children","author":"Aronoff","year":"2007"},{"key":"10.1016\/j.jtct.2022.06.013_bib0029","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2014.01.019","volume":"20","author":"Bubalo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbmt.2017.11.041","article-title":"Impact of dose-adjusted melphalan in obese patients undergoing autologous stem cell transplantation","volume":"24","author":"Shultes","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0031","first-page":"135","article-title":"Impact of weight-based melphalan dosing strategies in autologous hematopoietic stem-cell transplant for multiple myeloma","volume":"10","author":"Yeung","year":"2020","journal-title":"J Hematol Oncol Pharm"},{"issue":"2","key":"10.1016\/j.jtct.2022.06.013_bib0032","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.bbmt.2011.12.014","article-title":"Higher melphalan exposure is associated with improved overall survival for myeloma patients undergoing autologous transplant","volume":"18","author":"Shaw","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jtct.2022.02.014","article-title":"A review of propylene glycol-free melphalan conditioning for hematopoietic cell transplantation for multiple myeloma and light chain amyloidosis","volume":"28","author":"Hari","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.013_bib0034","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A phase IIB, multicenter, open-label, safety, and efficacy study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0035","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.bbmt.2020.08.030","article-title":"Propylene glycol-free melphalan versus PG-melphalan as conditioning for autologous hematopoietic cell transplantation for myeloma","volume":"26","author":"Monahan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0036","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V110.11.728.728","article-title":"A randomized comparison of total-marrow irradiation, busulfan and cyclophosphamide with tandem high-dose melphalan in patients with multiple myeloma","volume":"110","author":"Stefan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.013_bib0037","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1702167","volume":"25","author":"Desikan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0038","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2141.2005.05641.x","article-title":"High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study","volume":"130","author":"Fenk","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0039","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/bmt.2010.160","article-title":"Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma","volume":"46","author":"Kazmi","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0040","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/07357907.2010.550663","article-title":"Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma","volume":"29","author":"Beaven","year":"2011","journal-title":"Cancer Investig"},{"key":"10.1016\/j.jtct.2022.06.013_bib0041","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.leu.2404003","article-title":"Results of a phase I\/II trial adding carmustine (300 mg\/m2) to melphalan (200 mg\/m2) in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"20","author":"Comenzo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.06.013_bib0042","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/bmt.2011.106","article-title":"Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma","volume":"47","author":"Chen","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0043","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2017.208","article-title":"High-dose BCNU\/melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"53","author":"Sivaraj","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0044","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.clml.2015.05.008","article-title":"BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma","volume":"15","author":"Veeraputhiran","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.06.013_bib0045","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.06.013_bib0046","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","article-title":"Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach","volume":"19","author":"Blanes","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2022.06.013_bib0047","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial","volume":"6","author":"Bashir","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0048","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/bloodadvances.2020002590","article-title":"Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM","volume":"4","author":"Saini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.013_bib0049","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12935-021-02313-z","article-title":"Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg\/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis","volume":"21","author":"Gao","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jtct.2022.06.013_bib0050","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbmt.2013.02.013","article-title":"A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma","volume":"19","author":"Mark","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0051","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bmt.2016.94","article-title":"A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy","volume":"51","author":"Martino","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0052","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41409-019-0587-0","article-title":"High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma","volume":"54","author":"Gomez-Arteaga","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.013_bib0053","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.06.013_bib0054","doi-asserted-by":"crossref","unstructured":"Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du My\u00e9lome (IFM). Blood. 2010;115:32-37.","DOI":"10.1182\/blood-2009-06-229658"},{"key":"10.1016\/j.jtct.2022.06.013_bib0055","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.2021014635","article-title":"Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study","volume":"139","author":"Roussel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.013_bib0056","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.3109\/10428194.2012.685735","article-title":"High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy","volume":"53","author":"Huang","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.06.013_bib0057","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12185-013-1402-0","article-title":"Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma","volume":"98","author":"Miyamoto","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0058","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1080\/10428194.2020.1811275","article-title":"Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen","volume":"61","author":"Hagen","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.06.013_bib0059","first-page":"101","article-title":"Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma","volume":"68","author":"Ballestrero","year":"2002","journal-title":"J Haematol"},{"key":"10.1016\/j.jtct.2022.06.013_bib0060","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/10428190310001603957","article-title":"High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma","volume":"45","author":"Donato","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.06.013_bib0061","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbmt.2008.09.019","article-title":"Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial","volume":"14","author":"Qazilbash","year":"2008","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672201404X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672201404X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:03:22Z","timestamp":1763003002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672201404X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S266663672201404X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.013","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}